According to Cancer 2020, CD79B mutations were present in 53% of PCNSL cases, while MYD88 mutations were observed in 60%‒79% of cases; 20% of patients exhibited both mutations. This evidence concerns the gene CD79B and primary central nervous system lymphoma.